New gene independent RP treatment EA 2353
EA-2353 is a photoreceptor regeneration treatment for RP. It was granted orphan drug designation by the US FDA in May 2021，and it’s now in a phase 1/2a clinical study. EA-2353 is administered via intravitreal injection.
It reactivates the retinal stem cells in the ciliary epithelium around the iris. These actively differentiating cells migrate to the retina, where they mature into functional photoreceptors. This retinal structure and function regeneration could potentially reverse the loss of vision for RP patients regardless of the gene mutation type.
How to ensure the effectiveness and increase the success rate of the EA-2353 when it’s approved by the FDA?
The most important thing is to keep a healthy and balanced retinal environment, maintain the healthy optic nerve function and activate the dormant optic cells. Because this EA-2353 endogena material needs to be injected into the vitreous, near the retina at the back of the eye. However, without a healthy retinal environment, an inflamed surrounding could affect the treatment results and even end in a complete failure. In this case, an effective pretreatment, for example StemActiv supplement and microcurrent stimulation are two traits to a healthy retina.
StemActiv is made of organic natural herbs, which increase blood flow to the retina, improve oxygen and nutrients supply to activate the dormant rods and cones. It also contains anti-inflammatory, anti-oxidative and anti-apoptosis components. StemActiv restores the dormant optic cells function and optimizes the microenvironment of the retina.
AC STIM delivers specific frequency alternating current stimulation to enhance the activity and function of the retinal cells, reinforce visual signaling along the optic nerve and restore impaired vision. It also attracts adult stem cells to activate optic cells regeneration.
For more details and online order of StemActiv and AC STIM pretreatment for EA-2353 injection, please review: https://www.restorevisionherbs.com